Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma
Shots:
- The P-III TOURMALINE-MM2 study involves assessing of Ninlaro + lenalidomide + dexamethasone vs PBO + lenalidomide + dexamethasone in 705 transplant-ineligible patients with newly diagnosed MM
- The P-III TOURMALINE-MM2 study results: improvement in PFS (35.3 mos. vs 21.8 mos.); safety profile is consistent with the existing prescribing information
- Ninlaro is an oral proteasome inhibitor- approved in 60+ countries- including the US- EU & Japan with 10+ regulatory filing currently under review. In 2015- the US FDA has approved the triple regimen to treat patients with MM prior treated with at least one therapy
Click here to read full press release/ article
Ref: Takeda | Image: Takeda
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com